Donna M. Evon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Donna M. Evon has a total of 302 co-authors. Here are the top co-authors by number of shared publications:
Michael W. Fried
Division of Gastroenterology and Hepatology Department of Medicine University of North Carolina Chapel Hill NC USA
15 shared publicationsCarol E. Golin
Division of General Medicine and Clinical Epidemiology Department of Medicine Department of Health Behaviors University of North Carolina Chapel Hill NC USA
12 shared publications- Sarah R. Lieber
Department of Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern (UTSW) Medical Center, Dallas, Texas, USA
10 shared publications - Marina Serper
Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
9 shared publications Bryce B. Reeve
Center for Health Measurement, Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA
8 shared publications- Alfred Sidney Barritt
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA
7 shared publications
Latest Publications
- 16 September 2026
- Published by Wolters Kluwer Health in Hepatology
Lactulose with or without TeleTai-Chi for the prevention of falls: A sequential multiple assignment randomized controlled trial (LiveSMART)
Background and Aims: Falls are common and morbid for patients with cirrhosis, and patients have identified reducing fall risk as an unmet need and care priority. Approach and Results: This is a 24-week two-stage Sequential, Multiple Assignment Randomized Trial (SMART) at 4 centers in Michigan, Pennsylvania, and Texas enrolling 230 adults with cirrhosis and portal hypertension without prior overt hepatic encephalopathy (HE). There were 2 stages. In stage 1 (weeks 1–12), participants were randomized to lactulose or enhanced usual care (education on nutrition and fall prevention). In stage 2 (weeks 13–24), participants were randomized to TeleTai-Chi or enhanced usual care (exercise education). We evaluated the effectiveness of lactulose with or without TeleTai-Chi. The primary outcome was a hierarchical composite of death or transplantation, injurious falls, incident HE, and non-injurious falls. We used an intention-to-treat (ITT) win ratio (WR). Lactulose followed by TeleTai-Chi, compared with enhanced usual care, reduced injurious falls (4% vs. 12%) and non-injurious falls (19% vs. 32%), with no differences in overt HE (2% vs. 0%) or death/transplantation (0% vs. 0%). Compared with non-users, lactulose users experienced fewer injurious falls (3.5% vs. 8.5%), non-injurious falls (15.0% vs. 26.5%), and overt HE (1.8% vs. 2.6%), with no difference in death/transplantation or adverse events, resulting in a WR 2.3, 95% CI (1.3–4.0). Sequential lactulose/TeleTai-Chi reduced the risk of the primary outcome compared with usual care (WR 2.7, 95% CI (1.3–5.5). Conclusion: In patients with cirrhosis and portal hypertension without prior overt HE, lactulose reduced falls and fall-related harms. Sequential lactulose followed by TeleTai-Chi was also superior to enhanced usual care.
- 16 September 2026
- Published by Wolters Kluwer Health in Hepatology
Lactulose with or without TeleTai-Chi for the prevention of falls: A sequential multiple assignment randomized controlled trial (LiveSMART)
Background and Aims: Falls are common and morbid for patients with cirrhosis, and patients have identified reducing fall risk as an unmet need and care priority. Approach and Results: This is a 24-week two-stage Sequential, Multiple Assignment Randomized Trial (SMART) at 4 centers in Michigan, Pennsylvania, and Texas enrolling 230 adults with cirrhosis and portal hypertension without prior overt hepatic encephalopathy (HE). There were 2 stages. In stage 1 (weeks 1–12), participants were randomized to lactulose or enhanced usual care (education on nutrition and fall prevention). In stage 2 (weeks 13–24), participants were randomized to TeleTai-Chi or enhanced usual care (exercise education). We evaluated the effectiveness of lactulose with or without TeleTai-Chi. The primary outcome was a hierarchical composite of death or transplantation, injurious falls, incident HE, and non-injurious falls. We used an intention-to-treat (ITT) win ratio (WR). Lactulose followed by TeleTai-Chi, compared with enhanced usual care, reduced injurious falls (4% vs. 12%) and non-injurious falls (19% vs. 32%), with no differences in overt HE (2% vs. 0%) or death/transplantation (0% vs. 0%). Compared with non-users, lactulose users experienced fewer injurious falls (3.5% vs. 8.5%), non-injurious falls (15.0% vs. 26.5%), and overt HE (1.8% vs. 2.6%), with no difference in death/transplantation or adverse events, resulting in a WR 2.3, 95% CI (1.3–4.0). Sequential lactulose/TeleTai-Chi reduced the risk of the primary outcome compared with usual care (WR 2.7, 95% CI (1.3–5.5). Conclusion: In patients with cirrhosis and portal hypertension without prior overt HE, lactulose reduced falls and fall-related harms. Sequential lactulose followed by TeleTai-Chi was also superior to enhanced usual care.
- 20 August 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (9) , 263
Design and evaluation of PROMIS® fatigue and cognitive function short forms customized for adults with primary sclerosing cholangitis
Purpose The goal of the Primary Sclerosing Cholangitis Symptom Assessment Project (PSC-SAP) is to develop reliable and valid PSC symptom measures for use in clinical trials. This article describes the process for customizing PROMIS® Fatigue and PROMIS® Cognitive Function short forms for adults with PSC. Methods Relevant items from the PROMIS item banks were selected by matching findings from concept elicitation interviews. Participants were purposively selected for cognitive interviews if they were symptomatic with PSC-related fatigue or cognitive impairment and met general eligibility for PSC clinical trials. Interviews were recorded, transcribed, and coded. The precision of these PROMIS short forms for PSC to capture fatigue and cognitive function at different levels was analyzed. Results Participants’ (n = 22) open-ended descriptions of fatigue and cognitive impairment were consistent with prior concept elicitation interviews. From the 95-item PROMIS Fatigue item bank, 13 items were selected that directly aligned with fatigue concepts described during concept elicitation. Data from the cognitive interviews confirmed that both measures possessed strong content validity, with items perceived as clear, relevant, and comprehensive. The PROMIS Fatigue Short Form-PSC exceeded the 0.90 reliability threshold for T-scores between 36 and 79; the PROMIS Cognitive Function Short Form-PSC exceeded the 0.90 threshold between T-scores of approximately 22 and 60. Conclusion This study demonstrated the strength of PROMIS item banks to design PROMIS Fatigue and Cognitive Function short forms for adults with PSC. Once the psychometric properties of the PROMIS short forms are confirmed, these measures may be used to evaluate symptoms in PSC research and clinical trials.
- 20 August 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (9) , 263
Design and evaluation of PROMIS® fatigue and cognitive function short forms customized for adults with primary sclerosing cholangitis
Purpose The goal of the Primary Sclerosing Cholangitis Symptom Assessment Project (PSC-SAP) is to develop reliable and valid PSC symptom measures for use in clinical trials. This article describes the process for customizing PROMIS® Fatigue and PROMIS® Cognitive Function short forms for adults with PSC. Methods Relevant items from the PROMIS item banks were selected by matching findings from concept elicitation interviews. Participants were purposively selected for cognitive interviews if they were symptomatic with PSC-related fatigue or cognitive impairment and met general eligibility for PSC clinical trials. Interviews were recorded, transcribed, and coded. The precision of these PROMIS short forms for PSC to capture fatigue and cognitive function at different levels was analyzed. Results Participants’ (n = 22) open-ended descriptions of fatigue and cognitive impairment were consistent with prior concept elicitation interviews. From the 95-item PROMIS Fatigue item bank, 13 items were selected that directly aligned with fatigue concepts described during concept elicitation. Data from the cognitive interviews confirmed that both measures possessed strong content validity, with items perceived as clear, relevant, and comprehensive. The PROMIS Fatigue Short Form-PSC exceeded the 0.90 reliability threshold for T-scores between 36 and 79; the PROMIS Cognitive Function Short Form-PSC exceeded the 0.90 threshold between T-scores of approximately 22 and 60. Conclusion This study demonstrated the strength of PROMIS item banks to design PROMIS Fatigue and Cognitive Function short forms for adults with PSC. Once the psychometric properties of the PROMIS short forms are confirmed, these measures may be used to evaluate symptoms in PSC research and clinical trials.
- Open Access
- 20 August 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (9)
Symptom burden is associated with health-related quality of life in symptomatic adults with primary sclerosing cholangitis
Background: The Primary Sclerosing Cholangitis Symptom Assessment Project (PSC-SAP) is a research initiative aimed at developing regulatory-grade PSC-specific symptom measures. During the initial screening phase for PSC-SAP, patient-reported symptom data were collected from a cohort of symptomatic adults. The current study aims to comprehensively characterize a range of symptoms and identify predictors of symptom burden and mental and physical health-related quality of life (HRQOL). Methods: Adults were primarily recruited through the PSC Partners Patient Registry for this cross-sectional study. Eligible participants completed a telephone-based survey that screened for 13 PSC-associated symptoms experienced in the last month and collected sociodemographic, clinical, and HRQOL scores using the PROMIS (Patient-Reported Outcomes Measurement Information System) global health measure. Multivariable linear regressions were used to model outcomes of total symptom burden and HRQOL. Results: Among 126 symptomatic participants, 88% were White, 60% were female, and the mean age was 47 years. The most prevalent symptoms were fatigue (83%) and daytime drowsiness (73%), followed by >60% reporting anxiety, liver pain, brain fog, sleep disturbance, and pruritus. Female sex and cirrhosis were associated with higher symptom burden scores. Factors such as age, history of cholangitis attacks, and inflammatory bowel disease (IBD) were not. Adding a total symptom burden score to initial models substantially increased the explanation of variation in mental HRQOL (from 9% to 48%) and physical HRQOL (from 12% to 51%) scores. Conclusions: Among symptomatic adults living with PSC, 6 PSC symptoms emerged as highly prevalent. With total symptom burden strongly associated with mental and physical HRQOL, multisymptom assessments should be utilized in future HRQOL studies of PSC and may help improve clinical care for those suffering from PSC.
- 20 August 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (9)
Open AccessSymptom burden is associated with health-related quality of life in symptomatic adults with primary sclerosing cholangitis
Background: The Primary Sclerosing Cholangitis Symptom Assessment Project (PSC-SAP) is a research initiative aimed at developing regulatory-grade PSC-specific symptom measures. During the initial screening phase for PSC-SAP, patient-reported symptom data were collected from a cohort of symptomatic adults. The current study aims to comprehensively characterize a range of symptoms and identify predictors of symptom burden and mental and physical health-related quality of life (HRQOL). Methods: Adults were primarily recruited through the PSC Partners Patient Registry for this cross-sectional study. Eligible participants completed a telephone-based survey that screened for 13 PSC-associated symptoms experienced in the last month and collected sociodemographic, clinical, and HRQOL scores using the PROMIS (Patient-Reported Outcomes Measurement Information System) global health measure. Multivariable linear regressions were used to model outcomes of total symptom burden and HRQOL. Results: Among 126 symptomatic participants, 88% were White, 60% were female, and the mean age was 47 years. The most prevalent symptoms were fatigue (83%) and daytime drowsiness (73%), followed by >60% reporting anxiety, liver pain, brain fog, sleep disturbance, and pruritus. Female sex and cirrhosis were associated with higher symptom burden scores. Factors such as age, history of cholangitis attacks, and inflammatory bowel disease (IBD) were not. Adding a total symptom burden score to initial models substantially increased the explanation of variation in mental HRQOL (from 9% to 48%) and physical HRQOL (from 12% to 51%) scores. Conclusions: Among symptomatic adults living with PSC, 6 PSC symptoms emerged as highly prevalent. With total symptom burden strongly associated with mental and physical HRQOL, multisymptom assessments should be utilized in future HRQOL studies of PSC and may help improve clinical care for those suffering from PSC.
- 12 August 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Medication adherence and telehealth interventions after liver transplantation: A systematic review and meta-analysis
Medication adherence is critical to long-term graft and patient survival after liver transplantation (LT), yet the effectiveness of adherence-promoting interventions across the post-transplant survivorship continuum remains uncertain. We systematically reviewed interventions to improve medication adherence, including immunosuppressive regimen simplification, pharmacist-led or counseling strategies, behavioral and multicomponent programs, and technology-based interventions. We identified 33 studies: immunosuppressive regimen simplification (n=8), pharmacist-led or counseling strategies (n=6), behavioral or multicomponent programs (n=3), virtual visits/remote monitoring (n=9), and mobile or text-based tools (n=7). In pooled analyses of randomized trials, active interventions improved adherence versus usual care (OR 4.04, 95% CI 1.94–8.41), although heterogeneity was substantial. A higher prevalence of alcohol-associated liver disease was associated with weaker intervention effects. Regimen simplification, especially conversion from twice-daily to once-daily tacrolimus, showed consistent improvement in adherence while maintaining acceptable graft outcomes. Pharmacist-led interventions improved medication knowledge, dosing compliance, and drug monitoring. Telehealth interventions reduced travel burden and, in some studies, early readmissions and hospital stays. Overall, regimen simplification and structured multidisciplinary support appear most effective, but larger longitudinal trials with standardized adherence measures are needed.
- 12 August 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Medication adherence and telehealth interventions after liver transplantation: A systematic review and meta-analysis
Medication adherence is critical to long-term graft and patient survival after liver transplantation (LT), yet the effectiveness of adherence-promoting interventions across the post-transplant survivorship continuum remains uncertain. We systematically reviewed interventions to improve medication adherence, including immunosuppressive regimen simplification, pharmacist-led or counseling strategies, behavioral and multicomponent programs, and technology-based interventions. We identified 33 studies: immunosuppressive regimen simplification (n=8), pharmacist-led or counseling strategies (n=6), behavioral or multicomponent programs (n=3), virtual visits/remote monitoring (n=9), and mobile or text-based tools (n=7). In pooled analyses of randomized trials, active interventions improved adherence versus usual care (OR 4.04, 95% CI 1.94–8.41), although heterogeneity was substantial. A higher prevalence of alcohol-associated liver disease was associated with weaker intervention effects. Regimen simplification, especially conversion from twice-daily to once-daily tacrolimus, showed consistent improvement in adherence while maintaining acceptable graft outcomes. Pharmacist-led interventions improved medication knowledge, dosing compliance, and drug monitoring. Telehealth interventions reduced travel burden and, in some studies, early readmissions and hospital stays. Overall, regimen simplification and structured multidisciplinary support appear most effective, but larger longitudinal trials with standardized adherence measures are needed.
- Open Access
- 3 August 2026
- Published by Wiley in Liver International
- Vol. 46 (9) , e70814
Fatigue and Cognitive Impairment in Adults With Primary Sclerosing Cholangitis: Results From Concept Elicitation Interviews
Background and Aims: To understand the experience of fatigue and cognitive impairment in adults with symptomatic primary sclerosing cholangitis (PSC) as an essential first step towards developing PSC‐specific symptom measures. Methods: Purposeful sampling was used to identify 17 symptomatic adults from the PSC Symptom Assessment Project who met general trial eligibility criteria for in‐depth concept elicitation interviews focused on key PSC symptoms. Of these, twelve were interviewed in‐depth about fatigue and eleven about cognitive impairment. Interviews were conducted virtually, audio‐recorded, transcribed and analysed. The Theory of Unpleasant Symptoms guided the development of a PSC symptom conceptual framework. Results: Participants were on average 42 years old, 57% male, 71% White and 57% had inflammatory bowel disease. Half experienced fatigue and cognitive impairment daily, while others described varying frequencies of these symptoms. Most participants described fatigue getting progressively worse throughout the day, often requiring naps. Fatigue interfered with domestic duties, job responsibilities and family/social activities. Fatigue impacted mental health with frustration, sadness and guilt. Participants with cognitive impairment reported it ranged from mild to severe, with some unable to live independently or maintain employment. Working memory, verbal fluency, attention and processing speed were impacted. Fatigue and cognitive impairment frequently co‐occurred but could occur separately. Conclusions: PSC‐related fatigue and cognitive impairment impact daily, work‐related, emotional and social functioning in symptomatic adults. These qualitative findings inform the customization of PSC‐specific fatigue and cognitive function measures with strong content validity that is necessary for use in PSC research and clinical trials.
- 3 August 2026
- Published by Wiley in Liver International
- Vol. 46 (9) , e70814
Open AccessFatigue and Cognitive Impairment in Adults With Primary Sclerosing Cholangitis: Results From Concept Elicitation Interviews
Background and Aims: To understand the experience of fatigue and cognitive impairment in adults with symptomatic primary sclerosing cholangitis (PSC) as an essential first step towards developing PSC‐specific symptom measures. Methods: Purposeful sampling was used to identify 17 symptomatic adults from the PSC Symptom Assessment Project who met general trial eligibility criteria for in‐depth concept elicitation interviews focused on key PSC symptoms. Of these, twelve were interviewed in‐depth about fatigue and eleven about cognitive impairment. Interviews were conducted virtually, audio‐recorded, transcribed and analysed. The Theory of Unpleasant Symptoms guided the development of a PSC symptom conceptual framework. Results: Participants were on average 42 years old, 57% male, 71% White and 57% had inflammatory bowel disease. Half experienced fatigue and cognitive impairment daily, while others described varying frequencies of these symptoms. Most participants described fatigue getting progressively worse throughout the day, often requiring naps. Fatigue interfered with domestic duties, job responsibilities and family/social activities. Fatigue impacted mental health with frustration, sadness and guilt. Participants with cognitive impairment reported it ranged from mild to severe, with some unable to live independently or maintain employment. Working memory, verbal fluency, attention and processing speed were impacted. Fatigue and cognitive impairment frequently co‐occurred but could occur separately. Conclusions: PSC‐related fatigue and cognitive impairment impact daily, work‐related, emotional and social functioning in symptomatic adults. These qualitative findings inform the customization of PSC‐specific fatigue and cognitive function measures with strong content validity that is necessary for use in PSC research and clinical trials.
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1)
Symptom Network Analysis in Patients With Primary Sclerosing Cholangitis
Introduction: Patients with primary sclerosing cholangitis (PSC) experience numerous symptoms that impact quality of life. We sought to identify PSC‐specific symptom clusters and relationships between symptoms to better understand the lived experience of PSC patients. Methods: Presence and severity of 16 symptoms were identified from the international “Our Voices” survey collected by PSC Partners Seeking A Cure in 2020. LASSO‐regularized partial correlation network analysis was performed using Spearman correlations. The primary analysis utilized symptoms reported within the past 6 months of survey completion, with subgroup analyses conducted on patients with and without inflammatory bowel disease (IBD). Expected influence was computed to quantify the importance of each measure within networks. The Spinglass algorithm was employed to identify communities within networks. Results: Among 970 total participants, 54% were women, and 70% had IBD. Four dominant communities were identified across networks, including global symptoms, psychological symptoms, gastrointestinal symptoms, and cholestatic‐related symptoms. Of the 16 symptoms included in network analyses, fatigue and weakness had the most positive influence across multiple networks and across different communities within each network. Conclusions: The complex relationship between co‐occurring symptoms in PSC organizes into four dominant symptom clusters. FTG and WEA emerged as strongly influential symptoms that consistently were associated with other symptoms. Our analyses emphasize the complex, co‐occurring nature of PSC symptoms, identify highly influential symptoms, and highlight the need to develop patient‐reported outcome symptom measures to assess changes in these key symptoms in clinical trials and clinical practice.
- 1 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1)
Open AccessSymptom Network Analysis in Patients With Primary Sclerosing Cholangitis
Introduction: Patients with primary sclerosing cholangitis (PSC) experience numerous symptoms that impact quality of life. We sought to identify PSC‐specific symptom clusters and relationships between symptoms to better understand the lived experience of PSC patients. Methods: Presence and severity of 16 symptoms were identified from the international “Our Voices” survey collected by PSC Partners Seeking A Cure in 2020. LASSO‐regularized partial correlation network analysis was performed using Spearman correlations. The primary analysis utilized symptoms reported within the past 6 months of survey completion, with subgroup analyses conducted on patients with and without inflammatory bowel disease (IBD). Expected influence was computed to quantify the importance of each measure within networks. The Spinglass algorithm was employed to identify communities within networks. Results: Among 970 total participants, 54% were women, and 70% had IBD. Four dominant communities were identified across networks, including global symptoms, psychological symptoms, gastrointestinal symptoms, and cholestatic‐related symptoms. Of the 16 symptoms included in network analyses, fatigue and weakness had the most positive influence across multiple networks and across different communities within each network. Conclusions: The complex relationship between co‐occurring symptoms in PSC organizes into four dominant symptom clusters. FTG and WEA emerged as strongly influential symptoms that consistently were associated with other symptoms. Our analyses emphasize the complex, co‐occurring nature of PSC symptoms, identify highly influential symptoms, and highlight the need to develop patient‐reported outcome symptom measures to assess changes in these key symptoms in clinical trials and clinical practice.
- Open Access
- 20 November 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Group-based telehealth stress management—lifestyle interventions are feasible for patients with chronic liver disease
Background: Group-based, telehealth behavioral interventions may be efficient, effective, and acceptable treatment modalities for patients with chronic liver diseases; however, pilot feasibility and patient satisfaction data are needed to justify efficacy trials. Given the poor quality of life, symptoms, and health risk factors, patients with chronic hepatitis C–associated liver disease (HCV-LD) may benefit from psychosocial interventions. A pilot feasibility study of a videoconferencing-delivered cognitive behavioral coping skills intervention (“VC-CBCS”) was conducted to evaluate multiple indicators of feasibility, levels of patient satisfaction, and changes in patient-reported outcomes (PROs). Methods: We pilot tested a 14-week, 90-minute VC-CBCS intervention by conducting a small randomized controlled trial. Thirty-two adults with HCV-LD and high stress/symptom levels were randomized to the protocolized VC-CBCS intervention (n=24) or standard of care (n=8), in 4 waves of 7–9 participants in 2020–2021. Results: Based upon rates of approach to enrollment (60%), retention (84%), PRO data collection (99.4%), and session attendance (91%), a future efficacy trial appears highly feasible. Levels of participant satisfaction were encouraging for VC delivery, intervention content and structure, and group processes. Technological and behavioral issues were minor. Collection of in-home saliva testing was not feasible. Moderate to large pre–post-intervention effect sizes were observed for some mediators (perceived stress, coping, relaxation, self-efficacy, sleep hygiene), with some of these changes correlating with small to moderate improvements in mental health and symptoms (eg, depression, fatigue; effect size range: 0.23–0.47). No consistent patterns were evident between changes in eating and exercise behaviors and PROs. Conclusions: A group-based VC-CBCS intervention appears feasible and may address unmet psychosocial needs in patients living with chronic liver disease.
- 20 November 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Open AccessGroup-based telehealth stress management—lifestyle interventions are feasible for patients with chronic liver disease
Background: Group-based, telehealth behavioral interventions may be efficient, effective, and acceptable treatment modalities for patients with chronic liver diseases; however, pilot feasibility and patient satisfaction data are needed to justify efficacy trials. Given the poor quality of life, symptoms, and health risk factors, patients with chronic hepatitis C–associated liver disease (HCV-LD) may benefit from psychosocial interventions. A pilot feasibility study of a videoconferencing-delivered cognitive behavioral coping skills intervention (“VC-CBCS”) was conducted to evaluate multiple indicators of feasibility, levels of patient satisfaction, and changes in patient-reported outcomes (PROs). Methods: We pilot tested a 14-week, 90-minute VC-CBCS intervention by conducting a small randomized controlled trial. Thirty-two adults with HCV-LD and high stress/symptom levels were randomized to the protocolized VC-CBCS intervention (n=24) or standard of care (n=8), in 4 waves of 7–9 participants in 2020–2021. Results: Based upon rates of approach to enrollment (60%), retention (84%), PRO data collection (99.4%), and session attendance (91%), a future efficacy trial appears highly feasible. Levels of participant satisfaction were encouraging for VC delivery, intervention content and structure, and group processes. Technological and behavioral issues were minor. Collection of in-home saliva testing was not feasible. Moderate to large pre–post-intervention effect sizes were observed for some mediators (perceived stress, coping, relaxation, self-efficacy, sleep hygiene), with some of these changes correlating with small to moderate improvements in mental health and symptoms (eg, depression, fatigue; effect size range: 0.23–0.47). No consistent patterns were evident between changes in eating and exercise behaviors and PROs. Conclusions: A group-based VC-CBCS intervention appears feasible and may address unmet psychosocial needs in patients living with chronic liver disease.
- Open Access
- 21 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Opioid use after adult liver transplantation: Incidence, high-risk use, and adverse events in a large US cohort
Background: Opioid use contributes to significant morbidity, posing specific risks to liver transplant recipients (LTRs). This study aimed to characterize outpatient opioid use before and after liver transplantation (LT) and identify risk factors for high-risk, incident, and chronic use and related complications. Methods: Adult LTRs were identified from 2006 to 2021 in IQVIA PharMetrics Plus for Academics, a claims database representative of the commercially insured US population. Opioid use was evaluated 30–365 days after LT; high-risk use was defined as >50 morphine milligram equivalents (MMEs) per day or concurrent opioid–benzodiazepine use. Factors associated with use, including high-risk use, were identified using multivariable logistic regression analysis. Landmark analyses assessed the association between outpatient opioid use 30–120 days post-LT and incident adverse events (eg, psychiatric, substance use, chronic pain, fractures/falls, digestive). Results: Among 1338 LTRs, 899 (67.2%) received outpatient opioid prescriptions >30 days post-LT, of whom 553 (41%) had incident use; 122 (13.6%) had high-risk opioid use. Factors significantly associated with high-risk use were female sex, pre-LT opioid use, and psychiatric disorder. Opioid use was significantly associated with increased adverse events 120–365 days post-LT; 59% of LTRs with opioid use within 1 year of LT developed complications compared to 39% of non-opioid users during this window (p<0.001). In adjusted landmark analyses, low/moderate opioid use within 30–120 days post-LT was associated with 1.87 times the hazard of complications compared to no opioid use at 120 days post-LT (95% CI: 1.14–3.07) and high-risk opioid use was associated with 2.87 (95% CI: 1.05–7.85) times the hazard. Conclusions: Post-LT opioid use is associated with increased risk of adverse events. Caution is needed in opioid prescribing beyond the perioperative period, particularly for those with preexisting psychiatric conditions.
- 21 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Open AccessOpioid use after adult liver transplantation: Incidence, high-risk use, and adverse events in a large US cohort
Background: Opioid use contributes to significant morbidity, posing specific risks to liver transplant recipients (LTRs). This study aimed to characterize outpatient opioid use before and after liver transplantation (LT) and identify risk factors for high-risk, incident, and chronic use and related complications. Methods: Adult LTRs were identified from 2006 to 2021 in IQVIA PharMetrics Plus for Academics, a claims database representative of the commercially insured US population. Opioid use was evaluated 30–365 days after LT; high-risk use was defined as >50 morphine milligram equivalents (MMEs) per day or concurrent opioid–benzodiazepine use. Factors associated with use, including high-risk use, were identified using multivariable logistic regression analysis. Landmark analyses assessed the association between outpatient opioid use 30–120 days post-LT and incident adverse events (eg, psychiatric, substance use, chronic pain, fractures/falls, digestive). Results: Among 1338 LTRs, 899 (67.2%) received outpatient opioid prescriptions >30 days post-LT, of whom 553 (41%) had incident use; 122 (13.6%) had high-risk opioid use. Factors significantly associated with high-risk use were female sex, pre-LT opioid use, and psychiatric disorder. Opioid use was significantly associated with increased adverse events 120–365 days post-LT; 59% of LTRs with opioid use within 1 year of LT developed complications compared to 39% of non-opioid users during this window (p<0.001). In adjusted landmark analyses, low/moderate opioid use within 30–120 days post-LT was associated with 1.87 times the hazard of complications compared to no opioid use at 120 days post-LT (95% CI: 1.14–3.07) and high-risk opioid use was associated with 2.87 (95% CI: 1.05–7.85) times the hazard. Conclusions: Post-LT opioid use is associated with increased risk of adverse events. Caution is needed in opioid prescribing beyond the perioperative period, particularly for those with preexisting psychiatric conditions.
- 18 July 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (2) , 195-221
Survivorship interventions after liver transplantation (LT): A systematic review of interventions targeting physical and psychosocial well-being after LT
Despite improved survival, liver transplantation (LT) recipients need interventions that promote survivorship including better quality of life. This systematic review describes the goals and quality of existing post-LT interventions to identify gaps in post-LT care. Published manuscripts and registered clinical trials were identified using MEDLINE, PsycINFO, Cochrane, and Scopus from inception to January 1, 2024. Articles and trials were included if they described patient-facing interventions targeting health behaviors, patient-centered outcomes, or preventative health. Data extraction and intervention quality were assessed using applicable trial standards. A total of 61 published manuscripts and 18 registered trials were identified in: (1) alcohol (n=14); (2) diet/nutrition (n=7), education (n=5), symptom management (n=11), preventative health (n=8), physical activity (n=19), and psychosocial issues (n=15). Most interventions were in the early phases of development or pilot testing and targeted the perioperative period up to 1-year post-LT, with fewer interventions targeting >1-year post-LT. There is good evidence to suggest that multidisciplinary programs with integrated psychiatric resources can reduce alcohol relapse post-LT; in-person multimodal interventions including individualized counseling, exercise prescriptions, and educational materials, improved strength, body composition, and quality of life. Multidisciplinary clinics integrating education, free resources, and clinical exams are beneficial in skin cancer prevention and cardiovascular risk modification. The best supported psychosocial interventions include support groups and in-person individualized counseling. Limited high-quality studies exist in diet/nutrition and education. For post-LT survivorship interventions, there is wide variation in intervention quality and limited investigation beyond 1 year post-LT. There is good evidence supporting multidisciplinary clinics/programs to prevent alcohol relapse, enhance physical activity, and facilitate cancer screening. There is limited data on promoting post-LT education, as well as social work and caregiver interventions. Future research should consider these areas for study; high-quality interventions need to incorporate stakeholder input, target later LT survivorship stages, and apply consistent definitions of patient-centered outcomes using validated measures.
- 18 July 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (2) , 195-221
Survivorship interventions after liver transplantation (LT): A systematic review of interventions targeting physical and psychosocial well-being after LT
Despite improved survival, liver transplantation (LT) recipients need interventions that promote survivorship including better quality of life. This systematic review describes the goals and quality of existing post-LT interventions to identify gaps in post-LT care. Published manuscripts and registered clinical trials were identified using MEDLINE, PsycINFO, Cochrane, and Scopus from inception to January 1, 2024. Articles and trials were included if they described patient-facing interventions targeting health behaviors, patient-centered outcomes, or preventative health. Data extraction and intervention quality were assessed using applicable trial standards. A total of 61 published manuscripts and 18 registered trials were identified in: (1) alcohol (n=14); (2) diet/nutrition (n=7), education (n=5), symptom management (n=11), preventative health (n=8), physical activity (n=19), and psychosocial issues (n=15). Most interventions were in the early phases of development or pilot testing and targeted the perioperative period up to 1-year post-LT, with fewer interventions targeting >1-year post-LT. There is good evidence to suggest that multidisciplinary programs with integrated psychiatric resources can reduce alcohol relapse post-LT; in-person multimodal interventions including individualized counseling, exercise prescriptions, and educational materials, improved strength, body composition, and quality of life. Multidisciplinary clinics integrating education, free resources, and clinical exams are beneficial in skin cancer prevention and cardiovascular risk modification. The best supported psychosocial interventions include support groups and in-person individualized counseling. Limited high-quality studies exist in diet/nutrition and education. For post-LT survivorship interventions, there is wide variation in intervention quality and limited investigation beyond 1 year post-LT. There is good evidence supporting multidisciplinary clinics/programs to prevent alcohol relapse, enhance physical activity, and facilitate cancer screening. There is limited data on promoting post-LT education, as well as social work and caregiver interventions. Future research should consider these areas for study; high-quality interventions need to incorporate stakeholder input, target later LT survivorship stages, and apply consistent definitions of patient-centered outcomes using validated measures.
- 15 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (11) , 1826-1827
Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC
- 15 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (11) , 1826-1827
Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC